Tags : NLRP3 Inhibitors

Novartis to Acquire IFM Tre for its Clinical and Preclinical

Shots:  Novartis acquires IFM Tre, in all stock transaction for $1.575B. IFM Tre to receive $310M upfront & $1.265B milestones from Novartis. The transaction is expected to close in Q2’19 The focus of the acquisition is to expand Novartis’ immunomodulatory portfolio with the addition of IFM Tre’s one clinical (IFM-2427) and two preclinical programs of […]Read More